Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-390 vs Viread in Healthy Volunteers
NCT02589457Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir disoproxil aspartate in Chronic Hepatitis B (CHB) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Area Under the Curve to the last measurable concentration. Started Oct 2015; status: completed.
02
Drugs
tenofovir disoproxil aspartate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02589457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589457.